Collegium Pharmaceutical, Inc: Form 10-K for the period ended Dec 31, 2020
Filed with the SEC on Feb 25, 2021 and accepted by EDGAR at Feb 25, 2021, 16:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-10-01 to 2020-12-31 | $76.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2020-01-01 to 2020-12-31 | $310.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-10-01 to 2020-12-31 | $32.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months2020-01-01 to 2020-12-31 | $130.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-10-01 to 2020-12-31 | $44.3m | us-gaap:GrossProfit |
| Gross profit | 12 months2020-01-01 to 2020-12-31 | $179.8m | us-gaap:GrossProfit |
| Research and development | 3 months2020-10-01 to 2020-12-31 | $2.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2020-01-01 to 2020-12-31 | $9.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-10-01 to 2020-12-31 | $26.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2020-01-01 to 2020-12-31 | $113.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-10-01 to 2020-12-31 | $15.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2020-01-01 to 2020-12-31 | $56.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-10-01 to 2020-12-31 | $7.7m | us-gaap:InterestExpense |
| Interest expense | 12 months2020-01-01 to 2020-12-31 | $28.9m | us-gaap:InterestExpense |
| Income tax | 3 months2020-10-01 to 2020-12-31 | $304.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $830.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-10-01 to 2020-12-31 | $7.0m | us-gaap:NetIncomeLoss |
| Net income | 12 months2020-01-01 to 2020-12-31 | $26.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-10-01 to 2020-12-31 | $0.20 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | $0.76 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-10-01 to 2020-12-31 | $0.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2020-01-01 to 2020-12-31 | $0.78 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-10-01 to 2020-12-31 | 35,417,623 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2020-01-01 to 2020-12-31 | 35,151,353 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | $93.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $5.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-12-31 | $174.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $277.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $643.8m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $239.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $457.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $186.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-21-001814. Last ingested by Listed: Nov 10, 2026, 23:07 ET. Listed shows no prices and gives no investment advice.